吉妥珠单抗奥唑米星联合或不联合强化化疗治疗NPM1突变急性髓系白血病(AMLSG 09-09):一项随机、开放标签、多中心、3期试验
在德国和奥地利56家医院开展的开放标签3期试验,纳入588例新诊断NPM1突变急性髓系白血病患者,随机接受强化化疗联合或不联合吉妥珠单抗奥唑米星。主要终点无事件生存期和总生存期均未达到,但吉妥珠单抗奥唑米星组2年累积复发率显著降低(25% vs 37%),完全缓解率较低(47% vs 58%)。
要点
- 吉妥珠单抗奥唑米星未改善6个月无事件生存率(58% vs 53%,HR 0.83,p=0.10)和2年总生存率(73% vs 69%,HR 0.90,p=0.43)。
- 吉妥珠单抗奥唑米星组2年累积复发率显著降低(25% vs 37%,病因特异性HR 0.65,p=0.0028)。
- 吉妥珠单抗奥唑米星组完全缓解率较低(47% vs 58%,OR 0.63,p=0.0068),治疗相关死亡25例(4%)。
核心结论
- 试验主要终点无事件生存期和总生存期未达到。
- 吉妥珠单抗奥唑米星显示出抗白血病疗效,表现为累积复发率显著降低,提示可能减少挽救治疗需求。
- 作者认为吉妥珠单抗奥唑米星应加入NPM1突变急性髓系白血病成人患者的标准治疗。
研究设计与样本
- 开放标签、多中心、3期随机对照试验,在德国和奥地利56家医院开展。
- 纳入18岁及以上、新诊断NPM1突变急性髓系白血病、ECOG体能状态0-2的患者。
- 按年龄(18-60岁 vs >60岁)分层,1:1随机分配至标准组或吉妥珠单抗奥唑米星组,分配隐藏,参与者和研究者均未设盲。
- 共筛选600例,588例(女性315例,男性273例)随机分配:标准组296例,吉妥珠单抗奥唑米星组292例。
- 两组均接受2个周期诱导治疗(去甲氧柔红霉素、阿糖胞苷、依托泊苷)联合全反式维甲酸(ATRA),随后3个周期大剂量阿糖胞苷(>60岁者用中等剂量)联合ATRA;吉妥珠单抗奥唑米星组在诱导第1、2周期及巩固第1周期第1天静脉给予吉妥珠单抗奥唑米星3 mg/m2。
主要发现
- 6个月随访时短期无事件生存率:标准组53%(95%CI 47-59) vs 吉妥珠单抗奥唑米星组58%(95%CI 53-64),HR 0.83(95%CI 0.65-1.04),p=0.10。
- 2年总生存率:标准组69%(95%CI 63-74) vs 吉妥珠单抗奥唑米星组73%(95%CI 68-78),HR 0.90(95%CI 0.70-1.16),p=0.43。
- 完全缓解或CRi率:标准组267例(90%) vs 吉妥珠单抗奥唑米星组251例(86%),OR 0.67(95%CI 0.40-1.11),p=0.15;完全缓解或CRh率:标准组214例(72%) vs 吉妥珠单抗奥唑米星组195例(67%),OR 0.77(95%CI 0.54-1.10),p=0.18;完全缓解率:标准组172例(58%) vs 吉妥珠单抗奥唑米星组136例(47%),OR 0.63(95%CI 0.45-0.80),p=0.0068。
- 2年累积复发率:标准组37%(95%CI 31-43) vs 吉妥珠单抗奥唑米星组25%(95%CI 20-30),病因特异性HR 0.65(95%CI 0.49-0.86),p=0.0028;2年累积死亡率:标准组6%(95%CI 4-10) vs 吉妥珠单抗奥唑米星组7%(95%CI 5-11),HR 1.03(95%CI 0.59-1.81),p=0.91。
- 治疗相关3-4级不良事件:发热性中性粒细胞减少吉妥珠单抗奥唑米星组135例(47%) vs 标准组122例(41%);血小板减少261例(90%) vs 265例(90%);肺炎71例(25%) vs 64例(22%);脓毒症85例(29%) vs 73例(25%)。
关键数值与推荐
- 吉妥珠单抗奥唑米星用法:3 mg/m2,静脉给药,于诱导第1、2周期及巩固第1周期第1天。
- 诱导方案:去甲氧柔红霉素、阿糖胞苷、依托泊苷联合全反式维甲酸(ATRA);巩固方案:大剂量阿糖胞苷(>60岁者用中等剂量)联合ATRA。
临床怎么用
- 作者认为,基于累积复发率显著降低,吉妥珠单抗奥唑米星应加入NPM1突变急性髓系白血病成人患者的标准治疗。
- 作者认为,加用吉妥珠单抗奥唑米星可能减少这些患者的挽救治疗需求。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acute myeloid leukaemia with mutated NPM1 is associated with high CD33 expression and intermediate-risk cytogenetics. The aim of this study was to evaluate intensive chemotherapy with or without the anti-CD33 antibody-drug conjugate gemtuzumab ozogamicin in participants with newly diagnosed, NPM1-mutated acute myeloid leukaemia. METHODS: This open-label, phase 3 trial was conducted at 56 hospitals in Germany and Austria. Eligible participants were 18 years or older and had newly diagnosed NPM1-mutated acute myeloid leukaemia and an Eastern Cooperative Oncology Group performance status of 0-2. Participants were randomly assigned, using age as a stratification factor (18-60 years vs >60 years), 1:1 to the two treatment groups using allocation concealment; there was no masking of participants and investigators to treatment groups. Participants received two cycles of induction therapy (idarubicin, cytarabine, and etoposide) plus all-trans retinoic acid (ATRA) followed by three consolidation cycles of high-dose cytarabine (or an intermediate dose for those older than 60 years) and ATRA, without or with gemtuzumab ozogamicin (3 mg/m2 administered intravenously on day 1 of induction cycles 1 and 2, and consolidation cycle 1). The primary endpoints were short-term event-free survival and overall survival in the intention-to-treat population (overall survival was added as a co-primary endpoint after amendment four of the protocol on Oct 13, 2013). The secondary endpoints were event-free survival with long-term follow-up, rates of complete remission, complete remission with partial haematological recovery (CRh), and complete remission with incomplete haematological recovery (CRi), cumulative incidences of relapse and death, and number of days in hospital. This trial is registered with ClinicalTrials.gov (NCT00893399) and has been completed. FINDINGS: Between May 12, 2010, and Sept 1, 2017, 600 participants were enrolled, of which 588 (315 women and 273 men) were randomly assigned (296 to the standard group and 292 to the gemtuzumab ozogamicin group). No difference was found in short-term event-free survival (short-term event-free survival at 6-month follow-up, 53% [95% CI 47-59] in the standard group and 58% [53-64] in the gemtuzumab ozogamicin group; hazard ratio [HR] 0·83; 95% CI 0·65-1·04; p=0·10) and overall survival between treatment groups (2-year overall survival, 69% [63-74] in the standard group and 73% [68-78] in the gemtuzumab ozogamicin group; 0·90; 0·70-1·16; p=0·43). There was no difference in complete remission or CRi rates (n=267 [90%] in the standard group vs n=251 [86%] in the gemtuzumab ozogamicin group; odds ratio [OR] 0·67; 95% CI 0·40-1·11; p=0·15) and complete remission or CRh rates (n=214 [72%] vs n=195 [67%]; OR 0·77; 0·54-1·10; p=0·18), whereas the complete remission rate was lower with gemtuzumab ozogamicin (n=172 [58%] vs n=136 [47%]; OR 0·63; 0·45-0·80; p=0·0068). Cumulative incidence of relapse was significantly reduced by gemtuzumab ozogamicin (2-year cumulative incidence of relapse, 37% [95% CI 31-43] in the standard group and 25% [20-30] in the gemtuzumab ozogamicin group; cause-specific HR 0·65; 0·49-0·86; p=0·0028), and there was no difference in the cumulative incidence of death (2-year cumulative incidence of death 6% [4-10] in the standard group and 7% [5-11] in the gemtuzumab ozogamicin group; HR 1·03; 0·59-1·81; p=0·91). There were no differences in the number of days in hospital across all cycles between treatment groups. The most common treatment-related grade 3-4 adverse events were febrile neutropenia (n=135 [47%] in the gemtuzumab ozogamicin group vs n=122 [41%] in the standard group), thrombocytopenia (n=261 [90%] vs n=265 [90%]), pneumonia (n=71 [25%] vs n=64 [22%]), sepsis (n=85 [29%] vs n=73 [25%]). Treatment-related deaths were documented in 25 participants (4%; n=8 [3%] in the standard group and n=17 [6%] in the gemtuzumab ozogamicin group), mostly due to sepsis and infections. INTERPRETATION: The primary endpoints of the trial of event-free survival and overall survival were not met. However, an anti-leukaemic efficacy of gemtuzumab ozogamicin in participants with NPM1-mutated acute myeloid leukaemia is shown by a significantly lower cumulative incidence of relapse rate, suggesting that the addition of gemtuzumab ozogamicin might reduce the need for salvage therapy in these participants. The results from this study provide further evidence that gemtuzumab ozogamicin should be added in the standard of care treatment in adults with NPM1-mutated acute myeloid leukaemia. FUNDING: Pfizer and Amgen.
引用
- Döhner H, Weber D, Krzykalla J, et al. Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2023. PMID: 37187198. doi:10.1016/S2352-3026(23)00089-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。